BCL2 antibody (B-Cell CLL/lymphoma 2) (AA 41-54)

Details for Product anti-BCL2 Antibody No. ABIN967321, Supplier: Log in to see
Antigen
  • Bcl-2
  • PPP1R50
  • bcl-2
  • AW986256
  • C430015F12Rik
  • D630044D05Rik
  • D830018M01Rik
  • BCL-2
  • Bcl2
  • B-cell CLL/lymphoma 2
  • B cell leukemia/lymphoma 2
  • B-cell leukemia/lymphoma 2
  • B-cell leukemia/lymphoma 2-like
  • B-cell CLL/lymphoma 2 protein
  • BCL2
  • Bcl2
  • LOC100224888
  • bcl2
  • LOC100359045
  • BCL-2
Alternatives
anti-Human BCL2 antibody for Cell Culture
Epitope
AA 41-54
164
73
64
59
41
33
25
25
24
21
18
15
15
15
13
13
13
11
9
8
6
6
5
5
5
5
5
4
3
3
3
3
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Reactivity
Human
1001
253
211
54
28
22
18
18
5
4
4
3
2
2
2
2
Host
Mouse
549
517
19
6
2
2
2
Clonality
Monoclonal
Conjugate
This BCL2 antibody is un-conjugated
49
48
43
37
24
23
22
15
15
13
13
13
13
13
13
13
12
12
12
7
7
7
6
6
6
6
6
6
6
2
2
1
1
1
1
1
1
1
1
1
1
1
Application
Immunohistochemistry (Formalin-fixed Sections) (IHC (f)), Immunohistochemistry (Frozen Sections) (IHC (fro)), Flow Cytometry (FACS), Western Blotting (WB)
790
374
361
309
307
297
228
191
169
81
40
15
14
13
12
10
9
4
3
2
1
1
1
1
1
1
1
Options
Supplier
Log in to see
Supplier Product No.
Log in to see
Request

Get this product for free

It's quick and easy to submit your validation proposal. I want to validate this product

Learn more

Available images

Brand BD Pharmingen™
Immunogen Human Bcl-2 synthetic peptide aa. 41-54
Isotype IgG1
Characteristics 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
4. Source of all serum proteins is from USDA inspected abattoirs located in the United States.
Purification The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
Alternative Name Bcl-2 (BCL2 Antibody Abstract)
Background Bcl-2 is considered to be novel among proto-oncogenes because it blocks apoptosis (programmed cell death) in many cell types. Apoptosis is an active form of cellular suicide that typically requires new RNA and protein synthesis and is associated with distinct morphological changes including cell shrinkage, cytoplasm membrane blebbing, nuclear fragmentation and DNA degradation. Because Bcl-2 blocks apoptosis it may contribute to tumorigenisis by prolonging cell survival, rather than by accelerating the rate of cell proliferation. Human Bcl-2 protein migrates at a molecular weight of ~26 kDa by SDS-PAGE. Bcl-2/100 recognizes a 26 kDa band representing human Bcl-2. Additional minor bands at 27-31 kDa and 18-21 kDa may also be visualized. The 27-31 kDa upper band may represent a larger isoform, whereas the 18-21 kDa lower band may be an internal translation or proteolytic product, therefore, a synthetic peptide corresponding to amino acids 41-54 (GAAPAPGIFSSQPG) of human Bcl-2 was used as immunogen. This peptide sequence is not conserved between human and mouse. Bcl-2/100 does not cross-react with mouse Bcl-2. For detection of mouse Bcl-2 refer to clone 3F11 (ABIN967441), polyclonal rabbit anti-rat/mouse Bcl-2 antiserum, and polyclonal rabbit anti-mouse Bcl-2 antiserum.
Research Area Cancer, Apoptosis/Necrosis
Pathways MAPK Signaling, PI3K-Akt Signaling, Apoptosis, Caspase Cascade in Apoptosis, Regulation of Muscle Cell Differentiation, Cell-Cell Junction Organization, Skeletal Muscle Fiber Development, Autophagy, Smooth Muscle Cell Migration, Negative Regulation of intrinsic apoptotic Signaling
Application Notes Western Blot: Jurkat control lysate [50 µg (1 µg/µl)] is provided as a western blot positive control (Store lysate at -20° C). Additional control lysate (ABIN968537) is sold separately.
IHC: For paraffin-embedded sections, tissues should be fixed in either Bouin's fixative or formalin. For immunofluorescent staining and flow cytometry, our directly conjugated formats are recommended.
Comment

Related Products: ABIN968537

Restrictions For Research Use only
Format Liquid
Concentration 0.25 mg/mL
Buffer Aqueous buffered solution containing BSA, glycerol, and ≤0.09 % sodium azide.
Preservative Sodium azide
Precaution of Use This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage -20 °C
Storage Comment Store undiluted at -20°C.
Supplier Images
Flow Cytometry (FACS) image for anti-BCL2 antibody (B-Cell CLL/lymphoma 2) (AA 41-54) (ABIN967321) Profile of permeabilized lymphocytes analyzed on a FACScan (BDIS, San Jose, CA) (Firs...
Western Blotting (WB) image for anti-BCL2 antibody (B-Cell CLL/lymphoma 2) (AA 41-54) (ABIN967321) Western blot analysis of Bcl-2 (Second Panel). Lysate from Jurkat cells was probed wi...
Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)) image for anti-BCL2 antibody (B-Cell CLL/lymphoma 2) (AA 41-54) (ABIN967321) Formalin-fixed, paraffin-embedded tissue sections stained for Bcl-2 expression using ...
Product cited in: Krajewski, Tanaka, Takayama, Schibler, Fenton, Reed: "Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes." in: Cancer research, Vol. 53, Issue 19, pp. 4701-14, 1993 (PubMed).

Pezzella, Turley, Kuzu, Tungekar, Dunnill, Pierce, Harris, Gatter, Mason: "bcl-2 protein in non-small-cell lung carcinoma." in: The New England journal of medicine, Vol. 329, Issue 10, pp. 690-4, 1993 (PubMed).

Tanaka, Saito, Reed: "Structure-function analysis of the Bcl-2 oncoprotein. Addition of a heterologous transmembrane domain to portions of the Bcl-2 beta protein restores function as a regulator of cell survival." in: The Journal of biological chemistry, Vol. 268, Issue 15, pp. 10920-6, 1993 (PubMed).

Pezzella, Jones, Ralfkiaer, Ersbøll, Gatter, Mason: "Evaluation of bcl-2 protein expression and 14;18 translocation as prognostic markers in follicular lymphoma." in: British journal of cancer, Vol. 65, Issue 1, pp. 87-9, 1992 (PubMed).

Reed, Meister, Tanaka, Cuddy, Yum, Geyer, Pleasure: "Differential expression of bcl2 protooncogene in neuroblastoma and other human tumor cell lines of neural origin." in: Cancer research, Vol. 51, Issue 24, pp. 6529-38, 1992 (PubMed).

Williams: "Programmed cell death: apoptosis and oncogenesis." in: Cell, Vol. 65, Issue 7, pp. 1097-8, 1991 (PubMed).

Pezzella, Tse, Cordell, Pulford, Gatter, Mason: "Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation." in: The American journal of pathology, Vol. 137, Issue 2, pp. 225-32, 1990 (PubMed).